Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849207 · ClinicalTrials.gov registry record · Phase 1
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
A Phase 1 study of Hematologic Malignancies, sponsored by Ronald Paquette.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT05849207 is a Phase 1 study of Hematologic Malignancies that is actively recruiting participants, run by Ronald Paquette. The registered enrollment target is 26 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05849207, a Phase 1 study of Hematologic Malignancies, is actively recruiting participants, sponsored by Ronald Paquette.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05849207
The ClinicalTrials.gov registry entry for NCT05849207 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The listed sponsor is Ronald Paquette, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Cyclophosphamide is the first listed.
NCT05849207 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05849207 about?
NCT05849207 is a clinical study titled "Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant". The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
What is the current status of trial NCT05849207?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2023-10-24. Estimated completion is 2028-07-01.
What conditions does trial NCT05849207 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT05849207?
The interventions under investigation include: Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT05849207?
This trial is sponsored by Ronald Paquette, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849207 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.